GLUT4 mediates the protective function of gastrodin against pressure overload-induced cardiac hypertrophy

Biomed Pharmacother. 2023 May:161:114324. doi: 10.1016/j.biopha.2023.114324. Epub 2023 Mar 21.

Abstract

Gastrodia elata exhibits extensive pharmacological activity; its extract gastrodin (GAS) has been used clinically to treat cardiovascular diseases. In the present study, we examined the effect of GAS in a mice model of pathological cardiac hypertrophy, which was induced using transverse aortic constriction (TAC). Male C57BL/6 J mice underwent either TAC or sham surgery. GAS was administered post-surgically for 6 weeks and significantly improved the deterioration of cardiac contractile function caused by pressure overload, cardiac hypertrophy, and fibrosis in mice. Treatment with GAS for 6 weeks upregulated myosin heavy chain α and down-regulated myosin heavy chain β and atrial natriuretic peptide, while insulin increased the effects of GAS against cardiac hypertrophy. In vitro studies showed that GAS could also protect phenylephrine-induced cardiomyocyte hypertrophy, and these effects were attenuated by BAY-876, and increased by insulin. Taken together, our results suggest that the anti-hypertrophic effect of gastrodin depends on its entry into cardiomyocytes through GLUT4.

Keywords: Cardiac hypertrophy; GLUT4; Gastrodin.

MeSH terms

  • Animals
  • Cardiomegaly / drug therapy
  • Disease Models, Animal
  • Glucose Transporter Type 4 / metabolism
  • Insulins* / pharmacology
  • Insulins* / therapeutic use
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Myocytes, Cardiac
  • Myosin Heavy Chains*

Substances

  • gastrodin
  • Insulins
  • Myosin Heavy Chains
  • Glucose Transporter Type 4